Trial Profile
A Phase 1/2, Open-Label Study of Nivolumab (BMS-936558) in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors (CheckMate 077: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 077)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 25 Oct 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Carcinoma; Liver cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Acronyms CheckMate 077
- Sponsors Bristol-Myers Squibb
- 14 Mar 2022 Status changed from active, no longer recruiting to completed.
- 17 Sep 2021 Planned End Date changed from 3 Sep 2021 to 10 Oct 2021.
- 17 Sep 2021 Planned primary completion date changed from 3 Sep 2021 to 10 Oct 2021.